<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03512080</url>
  </required_header>
  <id_info>
    <org_study_id>UoL001324</org_study_id>
    <nct_id>NCT03512080</nct_id>
  </id_info>
  <brief_title>Warfarin Anticoagulation in Patients in Sub-Saharan Africa</brief_title>
  <acronym>War-PATH</acronym>
  <official_title>National Institute of Health Research (NIHR) Global Health Research Group on Warfarin Anticoagulation in Patients With Cardiovascular Disease in Sub-Saharan Africa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Liverpool</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research programme aims to translate expertise in warfarin anticoagulation from
      resource-rich to low and middle income countries (LMIC)settings with the goal of improving
      patient health outcomes.

      An observational study which will be used to develop warfarin dosing algorithms - the
      ultimate aim will be to ascertain whether these algorithms increase time in the therapeutic
      range, reduce bleeding and thrombotic risks, and clinic visits for International Normalised
      ratio (INR) monitoring. Two algorithms will be developed: the first will take into account
      clinical and geographical factors (&quot;clinical algorithm&quot;), while the second will also
      incorporate genetic factors in addition to the clinical and geographical factors (&quot;genetic
      algorithm&quot;). Patients will be recruited from sites in rural and urban Uganda, and in Cape
      Town, South Africa, to develop a clinical dosing algorithm. It is important to note that
      there is a wealth of literature data which will be used to define the clinical data that
      needs to be collected from these patients. To identify genetic factors in African patients,
      Genome-wide Association Study (GWAS) will be undertaken and any novel factors incorporated
      into the genetic algorithm - the percentage variation in warfarin dosing explained by the
      genetic algorithm will be compared with the clinical algorithm.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project focuses on an area unmet clinical need, oral anticoagulation, in patients with a
      variety of cardiovascular diseases. The investigators' ambition is to translate their
      internationally renowned expertise in warfarin anticoagulation into low and middle income
      country (LMIC) settings where it can significantly improve health. By working with policy
      makers, the investigators will provide the required evidence to allow national roll out of
      new practices, including the introduction of 1mg warfarin tablets as a quick win to improve
      dosing accuracy.

      This National Institute of Health Research (NIHR) Global Research Group is a collaboration
      between the University of Liverpool and two low and middle income countries (LMICs), Uganda
      and South Africa. It will focus on a clinically important non-communicable disease area which
      requires the use of anticoagulation.

      Anticoagulants, in particular warfarin, are used in these countries for the treatment of
      venous thromboembolism, valvular heart disease including rheumatic heart disease and
      prevention of strokes in patients with irregular heart rhythms (atrial fibrillation).
      Anticoagulation represents an unmet clinical need in Sub-Saharan Africa as patients either do
      not receive anticoagulation (because of difficulties in monitoring) or are poorly
      anticoagulated because of poor dosing guidelines. This results in potentially preventable
      morbidity and mortality which affects the poorer sectors of the population in particular. The
      investigators have extensive expertise in the United Kingdom and European Union of improving
      the use of warfarin through the development of novel dosing algorithms, which have now begun
      incorporating genetic factors.

      By contrast, in the investigators' two collaborating partner countries, no locally validated
      warfarin dosing algorithms exist, even those which only take into account clinical factors.
      This results in haphazard dosing with the attendant risks of thrombotic or bleeding
      complications. In both countries, monitoring requires frequent clinic visits, incurring
      transport costs and missed work days. Patients are often co-infected with human
      immunodeficiency virus (HIV) and/or Tuberculosis, requiring multiple concomitant medicines
      which complicate warfarin dosing and dose adjustment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">May 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of demographic, clinical and genetic factors in an African population that determine daily warfarin dosing requirements</measure>
    <time_frame>1 year</time_frame>
    <description>Completion of an audit to evaluate the current quality of anticoagulant services in Cape Town and rural and urban Uganda taking into account the indications, anticoagulant clinic set-up and quality of anticoagulation control.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Development of a clinical algorithm taking into account patient factors, co-medications and underlying disease</measure>
    <time_frame>3 years</time_frame>
    <description>Recruitment of patients currently on warfarin will be undertaken to identify clinical and other non-genetic factors associated with poor anticoagulation control to enable development of a warfarin clinical dosing algorithm. Data on patients' age, weight, height, gender, co-morbidities, co-medications, socio-economic factors, warfarin dose history and quality of anticoagulant control (International Normalised ratio (INR) measurement history) will be obtained for the algorithm development.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Development of a validated warfarin dosing algorithm taking into account both clinical and genetic factors</measure>
    <time_frame>3+ years</time_frame>
    <description>Evaluation of genes specific to the local African populations in Uganda and South Africa that can impact on anticoagulation control will be carried out, resulting in the development of a novel genetic dosing algorithm. In order to identify ethnic specific genetic factors, the investigators will undertake a Genome-wide Association Study (GWAS) on these patients, and any novel genetic factors will be incorporated into an improved dosing algorithm which will be compared with the original algorithm in terms of its ability to predict therapeutic dose.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Stable International Normalised Ratio</arm_group_label>
    <description>Consenting adult patients with either venous thromboembolism (VTE), atrial fibrillation (AF) on warfarin with a target International Normalised Ratio (INR) (INR range 2-3) or valvular heart disease with a target INR (INR range 3-4).</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Self-reported Black African ethnicity from Uganda and South Africa
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Consenting adult patients with either venous thromboembolism (VTE), atrial
             fibrillation (AF) on warfarin with a target International Normalised Ratio (INR) (INR
             range 2-3) or valvular heart disease with a target INR (INR range 3-4).

          2. On a stable maintenance dose for two consecutive clinic visits within the last six
             months, and the INR was in the therapeutic range at each of those visits.

          3. Age over 18 years.

          4. Self-reported Black African ethnicity.

          5. Signed or witnessed written (witnessed thumbprint for illiterate participants)
             informed consent.

        Exclusion Criteria:

          1. Patient unwilling to take part.

          2. Patient is, in the opinion of the investigator, not suitable to participate.

          3. Pregnant women.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Munir Pirmohamed</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Liverpool</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claire Hutchinson</last_name>
    <phone>44 151 794 5791</phone>
    <email>chutch@liverpool.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Cape Town</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karen Cohen</last_name>
    </contact>
    <investigator>
      <last_name>Karen Cohen</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Blockman</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Infectious Diseases Institute</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catriona Waitt</last_name>
    </contact>
    <investigator>
      <last_name>Mohammed Lamorde</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine Sekaggya</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catriona Waitt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>South Africa</country>
    <country>Uganda</country>
  </location_countries>
  <reference>
    <citation>Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996 Sep 7;348(9028):633-8.</citation>
    <PMID>8782752</PMID>
  </reference>
  <reference>
    <citation>Avery PJ, Jorgensen A, Hamberg AK, Wadelius M, Pirmohamed M, Kamali F; EU-PACT Study Group. A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy. Clin Pharmacol Ther. 2011 Nov;90(5):701-6. doi: 10.1038/clpt.2011.186. Epub 2011 Sep 28.</citation>
    <PMID>22012312</PMID>
  </reference>
  <reference>
    <citation>Pirmohamed M. Warfarin: almost 60 years old and still causing problems. Br J Clin Pharmacol. 2006 Nov;62(5):509-11.</citation>
    <PMID>17061959</PMID>
  </reference>
  <reference>
    <citation>Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, Kesteven P, Christersson C, Wahlstr√∂m B, Stafberg C, Zhang JE, Leathart JB, Kohnke H, Maitland-van der Zee AH, Williamson PR, Daly AK, Avery P, Kamali F, Wadelius M; EU-PACT Group. A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013 Dec 12;369(24):2294-303. doi: 10.1056/NEJMoa1311386. Epub 2013 Nov 19.</citation>
    <PMID>24251363</PMID>
  </reference>
  <reference>
    <citation>Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004 Jul 3;329(7456):15-9.</citation>
    <PMID>15231615</PMID>
  </reference>
  <reference>
    <citation>Sekaggya C, Nalwanga D, Von Braun A, Nakijoba R, Kambugu A, Fehr J, Lamorde M, Castelnuovo B. Challenges in achieving a target international normalized ratio for deep vein thrombosis among HIV-infected patients with tuberculosis: a case series. BMC Hematol. 2016 Jun 4;16:16. doi: 10.1186/s12878-016-0056-6. eCollection 2016.</citation>
    <PMID>27274846</PMID>
  </reference>
  <reference>
    <citation>Wadelius M, Pirmohamed M. Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J. 2007 Apr;7(2):99-111. Epub 2006 Sep 19. Review.</citation>
    <PMID>16983400</PMID>
  </reference>
  <reference>
    <citation>Cavallari LH, Perera MA. The future of warfarin pharmacogenetics in under-represented minority groups. Future Cardiol. 2012 Jul;8(4):563-76. doi: 10.2217/fca.12.31. Review.</citation>
    <PMID>22871196</PMID>
  </reference>
  <reference>
    <citation>Mouton JP, Mehta U, Parrish AG, Wilson DP, Stewart A, Njuguna CW, Kramer N, Maartens G, Blockman M, Cohen K. Mortality from adverse drug reactions in adult medical inpatients at four hospitals in South Africa: a cross-sectional survey. Br J Clin Pharmacol. 2015 Oct;80(4):818-26. doi: 10.1111/bcp.12567. Epub 2015 Jul 6.</citation>
    <PMID>25475751</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2018</study_first_submitted>
  <study_first_submitted_qc>April 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2018</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Liverpool</investigator_affiliation>
    <investigator_full_name>Professor Sir Munir Pirmohamed</investigator_full_name>
    <investigator_title>David Weatherall Chair of Medicine and National Health Service (NHS) Chair of Pharmacogenetics</investigator_title>
  </responsible_party>
  <keyword>Warfarin</keyword>
  <keyword>Anticoagulation</keyword>
  <keyword>Clinical Dosing Algorithm</keyword>
  <keyword>Genetic Dosing Algorithm</keyword>
  <keyword>International Normalised Ratio</keyword>
  <keyword>Uganda</keyword>
  <keyword>Cape Town</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>Genome-wide Association Study</keyword>
  <keyword>Stratified Medicine</keyword>
  <keyword>Pharmacogenetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

